CTMX (CytomX Therapeutics Inc) Likuiditas cepet

CytomX Therapeutics (CTMX) relies on licensing agreements with major pharmaceutical companies, ensuring a steady cash flow through patent royalties. The market price confirmed by this chart on GURU.Markets, where the metric stands at 9.74, correlates with the recruitment of leading biologists to develop innovative prodrugs. Meanwhile, the company minimizes its environmental impact by utilizing a virtual management model and outsourcing chemical synthesis.

The quick ratio determines the ability of a company to settle short-term debts using its most liquid assets. The calculation excludes inventories, focusing instead on cash and accounts receivable to assess actual solvency. By analyzing changes in the quick ratio, an investor can gauge the stability of the financial cushion. This is critical for CytomX Therapeutics (CTMX), as sanction barriers and the logistics crisis are slowing down clinical trials and the procurement of reagents.